Khaled Draghmeh, MD
Postdoctoral AssociateAbout
Research
Publications
2025
ERRATUM: Prevalence and Determinants of Metabolic Syndrome in Young Adults — Insights from a Jordanian Medical Student Cohort
A Saadeh N, Alshwayyat S, A. Abu-Dhaim O, I. Khraim K, O. Draghmeh K, F. Fallouh J, Y. Hijazi W, O. Al Aruri D, Z. Mughrabi Sabbagh A, R. Alkhaldi M, T. Haimour A. ERRATUM: Prevalence and Determinants of Metabolic Syndrome in Young Adults — Insights from a Jordanian Medical Student Cohort. Clinical Diabetology 2025, 14: 338-338. DOI: 10.5603/cd.110364.Commentaries, Editorials and LettersPrevalence and Determinants of Metabolic Syndrome in Young Adults — Insights from a Jordanian Medical Student Cohort
A Saadeh N, Alshwayyat S, A. Abu-Dhaim O, I. Khraim K, O. Draghmeh K, F. Fallouh J, Y. Hijazi W, O. Al Aruri D, Z. Mughrabi Sabbagh A, R. Alkhaldi M, T. Haimour A. Prevalence and Determinants of Metabolic Syndrome in Young Adults — Insights from a Jordanian Medical Student Cohort. Clinical Diabetology 2025, 14: 265-272. DOI: 10.5603/cd.105390.Peer-Reviewed Original ResearchA Review of the Evidence Surrounding Popular Cognitive Enhancers
Draghmeh K, Elmarasi M, Fuehrlein B. A Review of the Evidence Surrounding Popular Cognitive Enhancers. Current Psychopharmacologye 2025, 13 DOI: 10.2174/0122115560363501250609121229.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsA Review of Relapse in Opioid Use Disorder
Draghmeh K, Gold M, Fuehrlein B. A Review of Relapse in Opioid Use Disorder. Current Addiction Reports 2025, 12: 58. DOI: 10.1007/s40429-025-00672-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsUse disorderEnhance treatment retentionMindfulness-based therapyStress system dysregulationRelapse vulnerabilityOpioid use disorderNeurobiological mechanismsDopamine deficitMedication-Assisted TreatmentContingency managementTreatment retentionPsychosocial interventionsMechanisms of relapseReduce relapseBehavioral componentsReviewOpioid use disorderSignificant public health challengeSystem dysregulationPublic health challengeRelapse rateAt-risk populationsSocietal burdenEmergency therapyAt-riskRelapseEmerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists
Draghmeh K, Fuehrlein B. Emerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists. Journal Of Integrative Neuroscience 2025, 24: 26361. PMID: 40302255, DOI: 10.31083/jin26361.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSubstance use disordersCorticotropin-releasing factorTreatment of substance use disordersCorticotropin-releasing factor antagonistTreating substance use disordersDrug-seeking behaviorDopamine D3 receptorGlucagon-like peptide-1Reduce substance useUse of alcoholAddiction processD3R antagonistsReward modulationRelapse preventionD3 receptorsUse disorderStimulant useSubstance useGlucagon-like peptide-1 receptor agonistsPrevent relapseReceptor agonistsTarget different aspectsSignificant public health challengeAntagonistDisordersEpidemiology of Opioid Use, Misuse, and Overdoses
Draghmeh K, Gold M, Fuehrlein B. Epidemiology of Opioid Use, Misuse, and Overdoses. Current Addiction Reports 2025, 12: 36. DOI: 10.1007/s40429-025-00649-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsOpioid use disorderEpidemiology of opioid useComplex public health challengesMental health disordersRisk factorsPublic health challengeOpioid useHarm reduction programsSocioeconomic disadvantagePsychosocial interventionsAccess barriersHealth disordersHealth challengesReduction programsOverdose deathsImprove outcomesGenetic predispositionCollaborative effortsPolysubstance useTreatment retentionEpidemiologyInnovative therapiesIncreasing overdose deathsReviewThis reviewLimited accessibility